• argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023

  • The QbD Group launches its new Business & Communications division

    Monday September 18th 2023

  • AbolerIS Pharma announces €27 million in Series A financing to advance its novel treatment paradigm for autoimmune and inflammatory diseases

    Sunday September 17th 2023

  • argenx announces positive CHMP opinion for subcutaneous efgartigimod for generalized myasthenia gravis

    Friday September 15th 2023

  • New study discovers how neurons die in Alzheimer’s disease

    Friday September 15th 2023

  • Augustine Therapeutics expands its leadership team and R&D platform, enters regulatory development

    Tuesday September 12th 2023

  • Your news here?

  • SwiftPharma and the Population Council Pursue Agreement to Manufacture Griffithsin Needed for the Development of a Fast-Dissolving Insert for Protection Against HIV

    Friday September 8th 2023

  • The QbD Group acquires life sciences consultancy Azierta to reinforce its global vigilance services and expand its presence in Spain

    Tuesday September 5th 2023

  • SwiftPharma and AntoXa Corporation sign exclusive collaboration agreement to support the development and commercialization of a plant-made antibody against ricin exposure

    Friday September 1st 2023

Strategic Partners